Published in Infect Immun on May 01, 1999
Clostridium difficile-associated diarrhea in adults. CMAJ (2004) 4.27
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immun (2011) 1.24
Salmonella: from pathogenesis to therapeutics. J Bacteriol (2006) 1.22
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile. Infect Immun (1999) 1.09
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Pre-existing immunity against vaccine vectors--friend or foe? Microbiology (2012) 0.94
Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun (2005) 0.93
Recent developments for Pseudomonas vaccines. Hum Vaccin (2011) 0.91
Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine (2011) 0.91
Behavior of an Aeromonas hydrophila aroA live vaccine in water microcosms. Appl Environ Microbiol (2004) 0.86
Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein. Infect Immun (2001) 0.86
The identification of plant lectins with mucosal adjuvant activity. Immunology (2001) 0.84
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum Vaccin Immunother (2012) 0.84
Virulence attenuation and live vaccine potential of aroA, crp cdt cya, and plasmid-cured mutants of Salmonella enterica serovar Abortusovis in mice and sheep. Infect Immun (2005) 0.83
Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein. Vaccine (2009) 0.82
Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect Immun (2004) 0.79
A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters. Hum Vaccin Immunother (2015) 0.77
Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A. PLoS One (2015) 0.77
The protective effect of recombinant Lactococcus lactis oral vaccine on a Clostridium difficile-infected animal model. BMC Gastroenterol (2013) 0.77
Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity. Toxins (Basel) (2014) 0.76
Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response. Vaccine (2013) 0.76
Recombinant lipoprotein-based vaccine candidates against C. difficile infections. J Biomed Sci (2015) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J (1978) 8.47
Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J Exp Med (1994) 5.78
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
The mucosal immune system: from fundamental concepts to vaccine development. Vaccine (1992) 3.99
Pseudomembranous colitis. J Clin Pathol (1977) 3.93
Neonatal tetanus in the world today. Bull World Health Organ (1984) 3.22
The role of nasopharyngeal lymphoid tissue. Immunol Today (1992) 3.19
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology (N Y) (1992) 2.38
Management and control of a large outbreak of diarrhoea due to Clostridium difficile. J Hosp Infect (1994) 1.91
A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun (1995) 1.91
Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis (1993) 1.90
Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol (1994) 1.73
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology (1992) 1.62
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun (1997) 1.54
Antibiotic-associated pseudomembranous colitis: an epidemiologic investigation of a cluster of cases. J Infect Dis (1982) 1.53
Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect (1992) 1.52
Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine (1992) 1.46
Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect Immun (1990) 1.42
Expression of LacZ from the htrA, nirB and groE promoters in a Salmonella vaccine strain: influence of growth in mammalian cells. FEMS Microbiol Lett (1995) 1.40
Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun (1998) 1.38
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun (1997) 1.34
Restriction endonuclease DNA analysis of Clostridium difficile. J Clin Microbiol (1987) 1.33
Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding. Gastroenterology (1992) 1.32
Alternate routes of invasion may affect pathogenesis of Salmonella typhimurium in swine. Infect Immun (1995) 1.25
Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect Immun (1997) 1.23
Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide. Infect Immun (1991) 1.21
Systemic and mucosal immune responses in mice orally immunized with avirulent Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutinin. Infect Immun (1994) 1.18
Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc Natl Acad Sci U S A (1994) 1.16
Salmonella typhimurium delta aroA delta aroD mutants expressing a foreign recombinant protein induce specific major histocompatibility complex class I-restricted cytotoxic T lymphocytes in mice. Infect Immun (1993) 1.14
Differential induction of carrier antigen-specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice. Infect Immun (1995) 1.13
Immunization with synthetic peptides containing epitopes of the class 1 outer-membrane protein of Neisseria meningitidis: production of bactericidal antibodies on immunization with a cyclic peptide. J Gen Microbiol (1993) 1.03
Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect Immun (1997) 1.02
Quantitative study of antibiotic-induced susceptibility to Clostridium difficile enterocecitis in hamsters. Antimicrob Agents Chemother (1990) 0.99
Expression and immunogenicity of an Echinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vaccine strains. Infect Immun (1997) 0.96
Delivery of the Pertactin/P.69 polypeptide of Bordetella pertussis using an attenuated Salmonella typhimurium vaccine strain: expression levels and immune response. Vaccine (1996) 0.92
The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits. J Med Microbiol (1987) 0.92
Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: the influence of liposomes and adjuvants on the production of a bactericidal immune response. Microb Pathog (1996) 0.89
The effects of Clostridium difficile crude toxins and purified toxin A on stripped rabbit ileal mucosa in Ussing chambers. J Med Microbiol (1987) 0.83
Clostridium difficile toxin A binding to human intestinal epithelial cells. J Med Microbiol (1997) 0.82
The genome sequence of the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences. Nature (2000) 17.14
Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature (2001) 15.44
Genome sequence of Yersinia pestis, the causative agent of plague. Nature (2001) 14.36
The transposon Tn1 as a probe for studying ColE1 structure and function. Mol Gen Genet (1977) 8.71
Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol (1998) 6.12
A novel EspA-associated surface organelle of enteropathogenic Escherichia coli involved in protein translocation into epithelial cells. EMBO J (1998) 4.53
Whole genome comparison of Campylobacter jejuni human isolates using a low-cost microarray reveals extensive genetic diversity. Genome Res (2001) 4.09
Analysis of sequences transposed by complementation of two classes of transposition-deficient mutants of Tn3. J Bacteriol (1978) 3.69
Identification and characterization of TnphoA mutants of Salmonella that are unable to pass through a polarized MDCK epithelial cell monolayer. Mol Microbiol (1988) 3.59
The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol (1991) 3.52
Detection of intimins alpha, beta, gamma, and delta, four intimin derivatives expressed by attaching and effacing microbial pathogens. J Clin Microbiol (1998) 3.50
Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun (1988) 3.44
IgA production without mu or delta chain expression in developing B cells. Nat Immunol (2001) 3.26
The HtrA family of serine proteases. Mol Microbiol (1997) 3.14
Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. Proc Natl Acad Sci U S A (1989) 3.13
Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II. Effects on microbial proliferation and host survival in vivo. J Exp Med (2000) 3.12
Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol (2006) 3.05
Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo. Infect Immun (1989) 3.00
Characterization of the C-terminal domains of intimin-like proteins of enteropathogenic and enterohemorrhagic Escherichia coli, Citrobacter freundii, and Hafnia alvei. Infect Immun (1994) 2.85
Molecular cloning and expression of Campylobacter pylori species-specific antigens in Escherichia coli K-12. Infect Immun (1989) 2.81
Salmonella: immune responses and vaccines. Vet J (2001) 2.68
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A (1995) 2.63
Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun (1999) 2.50
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Role of intimin and bundle-forming pili in enteropathogenic Escherichia coli adhesion to pediatric intestinal tissue in vitro. Infect Immun (1998) 2.41
Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology (N Y) (1992) 2.38
Nucleotide sequence of two genes from Helicobacter pylori encoding for urease subunits. Nucleic Acids Res (1990) 2.38
A lethal role for lipid A in Salmonella infections. Mol Microbiol (1998) 2.30
Expression of a cloned Staphylococcus aureus alpha-hemolysin determinant in Bacillus subtilis and Staphylococcus aureus. Infect Immun (1983) 2.28
Genetic and biochemical evidence of a Campylobacter jejuni capsular polysaccharide that accounts for Penner serotype specificity. Mol Microbiol (2000) 2.28
Single-primer PCR procedure for rapid identification of transposon insertion sites. Biotechniques (2000) 2.25
Detection of pathogenic Yersinia enterocolitica by the polymerase chain reaction. Lancet (1990) 2.23
Bacterial copper- and zinc-cofactored superoxide dismutase contributes to the pathogenesis of systemic salmonellosis. Mol Microbiol (1997) 2.23
Genetic analysis of K88-mediated adhesion of enterotoxigenic Escherichia coli. Nature (1981) 2.21
Polypeptides expressed in Escherichia coli K-12 minicells by transposition elements Tn1 and Tn3. J Bacteriol (1979) 2.17
Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun (1996) 2.14
Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect Immun (1999) 2.14
The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis. Infect Immun (2000) 2.10
Comparison of the Escherichia coli K-12 genome with sampled genomes of a Klebsiella pneumoniae and three salmonella enterica serovars, Typhimurium, Typhi and Paratyphi. Nucleic Acids Res (2000) 2.07
Molecular, immunological, and biological characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.07
Evaluation of Salmonella typhimurium strains harbouring defined mutations in htrA and aroA in the murine salmonellosis model. Microb Pathog (1992) 2.04
Cloning, expression, and mapping of the Staphylococcus aureus alpha-hemolysin determinant in Escherichia coli K-12. Infect Immun (1983) 2.03
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med (1998) 1.98
Binding of intimin from enteropathogenic Escherichia coli to Tir and to host cells. Mol Microbiol (1999) 1.95
Salmonella typhimurium aroA mutants as carriers of the Escherichia coli heat-labile enterotoxin B subunit to the murine secretory and systemic immune systems. Microb Pathog (1987) 1.93
Expression of a gene for glucan-binding protein from Streptococcus mutans in Escherichia coli. J Gen Microbiol (1985) 1.93
Phase variation of a beta-1,3 galactosyltransferase involved in generation of the ganglioside GM1-like lipo-oligosaccharide of Campylobacter jejuni. Mol Microbiol (2000) 1.85
Salmonella enterica serovar Typhi possesses a unique repertoire of fimbrial gene sequences. Infect Immun (2001) 1.83
An attenuated aroA Salmonella typhimurium vaccine elicits humoral and cellular immunity to cloned beta-galactosidase in mice. J Infect Dis (1987) 1.81
The Campylobacter jejuni general glycosylation system is important for attachment to human epithelial cells and in the colonization of chicks. Microbiology (2004) 1.79
Characterization of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression. Infect Immun (1994) 1.79
Intimin from enteropathogenic Escherichia coli restores murine virulence to a Citrobacter rodentium eaeA mutant: induction of an immunoglobulin A response to intimin and EspB. Infect Immun (1996) 1.76
Serology of typhoid fever in an area of endemicity and its relevance to diagnosis. J Clin Microbiol (2001) 1.75
Helicobacter pylori possesses two CheY response regulators and a histidine kinase sensor, CheA, which are essential for chemotaxis and colonization of the gastric mucosa. Infect Immun (2000) 1.75
Molecular characterization of a carboxy-terminal eukaryotic-cell-binding domain of intimin from enteropathogenic Escherichia coli. Infect Immun (1995) 1.75
Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today (1999) 1.74
Role of ompR-dependent genes in Salmonella typhimurium virulence: mutants deficient in both ompC and ompF are attenuated in vivo. Infect Immun (1991) 1.74
Role of bacterial intimin in colonic hyperplasia and inflammation. Science (1999) 1.71
Interleukin-12 is required for control of the growth of attenuated aromatic-compound-dependent salmonellae in BALB/c mice: role of gamma interferon and macrophage activation. Infect Immun (1998) 1.69
The involvement of tumor necrosis factor in immunity to Salmonella infection. J Immunol (1991) 1.68
Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. Eur J Immunol (1991) 1.67
Igh-6(-/-) (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent Salmonella enterica serovar typhimurium and show impaired Th1 T-cell responses to Salmonella antigens. Infect Immun (2000) 1.67
Multiple N-acetyl neuraminic acid synthetase (neuB) genes in Campylobacter jejuni: identification and characterization of the gene involved in sialylation of lipo-oligosaccharide. Mol Microbiol (2000) 1.66
Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol (2001) 1.65
Construction and characterization of a Yersinia enterocolitica O:8 high-temperature requirement (htrA) isogenic mutant. Infect Immun (1996) 1.64
The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins. J Biol Chem (1996) 1.64
Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun (2000) 1.63
Down regulation of intimin expression during attaching and effacing enteropathogenic Escherichia coli adhesion. Infect Immun (1997) 1.63
Biofilm formation in Campylobacter jejuni. Microbiology (2006) 1.60
Characterization of an isogenic mutant of Streptococcus pyogenes Manfredo lacking the ability to make streptococcal acid glycoprotein. Infect Immun (2000) 1.60
Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect Immun (2001) 1.60
Cloning, and expression in Escherichia coli K-12, of the chromosomal hemolysin (phospholipase C) determinant of Pseudomonas aeruginosa. J Bacteriol (1983) 1.58
Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7. Gut (2002) 1.55
Development of signature-tagged mutagenesis in Burkholderia pseudomallei to identify genes important in survival and pathogenesis. Infect Immun (2006) 1.54
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun (1997) 1.54
Phospholipase C and haemolytic activities of Clostridium perfringens alpha-toxin cloned in Escherichia coli: sequence and homology with a Bacillus cereus phospholipase C. Mol Microbiol (1989) 1.53
Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis. Infect Immun (1992) 1.52
The molecular mechanisms of severe typhoid fever. Trends Microbiol (2001) 1.51
Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine (2001) 1.49
Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotechnol (1996) 1.47
Structure of the cell-adhesion fragment of intimin from enteropathogenic Escherichia coli. Nat Struct Biol (1999) 1.46
Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine. Vaccine (1992) 1.46
A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun (2002) 1.45
Development and application of an insertional system for gene delivery and expression in Campylobacter jejuni. Appl Environ Microbiol (2005) 1.44
Characterization of glucosyltransferase expressed from a Streptococcus sobrinus gene cloned in Escherichia coli. J Gen Microbiol (1987) 1.42
Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier. Infect Immun (1990) 1.42
[Duration and quality of postoperative analgesia after brachial plexus block for shoulder surgery: ropivacaine 0.5% versus ropivacaine 0.5% plus clonidine]. Rev Esp Anestesiol Reanim (2002) 1.42